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Abstract
Introduction: Macrophage activating syndrome is a severe, potentially life-threatening condition
that may accompany Still's disease. It is characterized by fever, hepatosplenomegaly,
lymphadenopathy, severe cytopenia, serious liver dysfunction, coagulopathy and neurologic
involvement. The principal treatment for patients with this syndrome includes etoposide 150 mg/
2 M twice a week for two weeks, dexamethasone 10 mg/2 M for two weeks and cyclosporine 3
mg/kg to 5 mg/kg for a longer period. Cases of relapse of macrophage activating syndrome are
relatively rare.
Case presentation: We describe the case of a 15-year-old Iraqi girl with Still's disease who
developed macrophage activating syndrome with acute respiratory distress syndrome that
required resuscitation and mechanical ventilation. Following intensive treatment, including high
dose steroids and cyclosporine, the patient improved significantly. Two weeks after cyclosporine
was discontinued, however, she was readmitted with an acute relapse of macrophage activating
syndrome manifested by spiking fever, arthralgias, maculopapular rash and leukocytosis. This time
the patient recovered following the reintroduction of treatment with cyclosporine and the addition
of mycophenolate mofetil (Cellcept).
Conclusion: We believe that cyclosporine is a cornerstone for the treatment of Still's disease. We
recommend continuing this medication for several weeks following the patient's clinical recovery
in order to prevent macrophage activating syndrome relapses.
Introduction
Macrophage activating syndrome (MAS) is a severe,
potentially life-threatening condition that is characterized
by fever, hepatosplenomegaly, lymphadenopathy, severe
cytopenia, severe liver dysfunction, coagulopathy and
neurological involvement [1]. The principal treatment for
patients with this syndrome includes etoposide 150 mg/2
M twice a week for two weeks, dexamethasone 10 mg/2 M
for two weeks and cyclosporine 3 mg/kg to 5 mg/kg for a
longer period of time. Relapsing cases of MAS are rela-
tively rare. However, there are several case reports that
describe a relapse happening after a short treatment or
after the dose of cyclosporine was decreased rapidly [1].
Still's disease (SD) is a rheumatic disease of unknown eti-
ology characterized by prolonged fever, arthralgias and/or
arthritis and maculopapular rash. One of its grave compli-
cations is MAS, which can occur in up to 15% of reported
cases [2].
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We describe a rare case of a young patient with SD who
presented with an acute relapsing pattern of MAS. Follow-
ing intensive treatment, she recovered and has remained
free of symptoms for the past 20 months.
Case presentation
A 15-year-old Iraqi girl was admitted with a fever of 39°C
which lasted for more than two weeks. A week prior to
admission, she had complained of a sore throat, fever and
maculopapular rash on her limbs, abdomen, palms and
back. The patient was treated with doxycycline 150 mg
twice a day, but due to her prolonged fever she was hospi-
talized. On admission, her physical examination was
unremarkable. However, her blood count revealed leuko-
cytosis of 23,000 (4000 to 10,000/mm3), with 90% neu-
trophils, hemoglobin of 12.6 Gr% (12 to 16 Gr% with
MCV 75 fl (77 to 91 fl)), erythrocyte sedimentation rate
(ESR) at 92 mm/1 hour, C-reactive protein (CRP) at 16 (0-
1 mg%) and serum ferritin level at 2267 ng/ml (10 to 120
ng/ml).
The patient's electrolytes, kidney and liver functions and
coagulation profile were all normal. Her antinuclear anti-
bodies, rheumatoid factor, c-ANCA, p-ANCA, anticardiol-
ipin antibodies, lupus anticoagulant, antiparietal cell
antibodies, anti-smooth muscle antibodies, anti-histone
antibodies and anti-mitochondrial antibodies all showed
negative results. Serological tests for CMV, EBV, HSV,
HAV, HBV, HCV, HIV, adenovirus, parainfluenza, Cox-
sackie, influenza, Toxoplasma and Brucella were all nega-
tive. Serology for parvovirus was positive for IgG
antibodies as well as for Coxiella burnetii antibodies (Q-
fever). A total body computed tomography (CT) scan was
performed but did not show any pathology except for a
16-cm enlarged spleen. Bone marrow (BM) biopsy
showed no evidence of lymphoma or any other type of
malignancy.
Based on the patient's clinical and laboratory studies, a
diagnosis of Still's disease was made. Three days after
admission to the hospital, her liver enzymes became ele-
vated. Two days later, the patient complained of shortness
of breath with saturation of 85% at room air. Her chest X-
rays were compatible with acute respiratory distress syn-
drome (ARDS). Her serum ferritin level rose to 10,648 ng/
ml; her CRP rose to 27.7; and her ESR was at 102 mm/1
hour. A complete blood count showed anemia with
hemoglobin values of 7.7 Gr%, a platelet count of 75,000
Gr% and white blood cell count of 18,000 (neutrophils
93%).
The patient's liver function tests showed the following
results: ALT 101 U/l (6 to 53 U/l), AST 369 U/L (2 to 60
U/l), alkaline phosphatase 329 U/l (40 to 200 U/l), GGTP
1055 U/L (10 to 80 U/l), total bilirubin 39 micromol/l (0
to 17 micromol/l), and LDH 10,800 U/l (300 to 620 U/l).
Her blood gases showed PO2  76 mmHg (85 to 90
mmHg), PCO2 31.8 mm/Hg (30 to 44 mmHg), HCO3
17.1 mmol/l (18 to 24 mmol/l) and pH 7.34 (7.38 to
7.42). Her coagulation profile disclosed a new alteration
in the INR (international normalized rate) with values of
1.57 (1 to 1.4) and hypofibrinogenemia of 90 mg% (nor-
mal values at 140 to 400 mg%). Polymerase chain reac-
tion (PCR) tests for CMV, EBV and HSV were performed
on the patient and the results were all negative. A second
BM biopsy, which was performed in order to rule out
malignancy (possibly indicated by spiking fever, arthral-
gias, sore throat, leukocytosis and maculopapular rash),
revealed impressive hemophagocytosis. The serum level
of beta 2 microglobilin was higher than 12,000 mg/ml
(normal value <2000), serum IL-2 receptor (IL-2R) was
1000 IU/ml (normal value <500 IU/ml) and serum tumor
necrosis factor (TNF) was lower than 20 pg/ml. The
patient was transferred to the intensive care unit and was
intubated and ventilated with high positive end expiratory
pressure (PEEP) levels.
A diagnosis of SD associated MAS was made and the
patient was treated with high-dose intravenous methyl-
prednisolone 1 g daily for three days, cyclosporine 5 mg/
kg daily and supportive noradrenalin due to her low
blood pressure (50/30 mmHg). With this treatment her
fever gradually diminished after two days and laboratory
values showed a slow improvement: a decline in leukocy-
tosis to normal range 9.5 (4-0 10E9/l) with 75% neu-
trophils, a decline in serum ferritin levels to 900 ng/ml
(10 to 120 ng/ml), ESR at 30 mm/1 hour and CRP at 2.9.
Her serum fibrinogen and the coagulation profile became
normal. Her platelet count normalized after nine days of
treatment. Her repeated serum level of beta 2 microglobi-
lin declined to 2600 mg/ml (normal value <2000). Her
serum IL-2R was 560 IU/ml (normal value <500 IU/ml)
and her serum TNF was lower than 20 pg/ml.
Due to the patient's clinical and laboratory improvement,
the dose of cyclosporine was reduced to 3 mg/kg and that
of solumedrol was reduced to 100 mg three times daily.
After 10 days, the patient was successfully extubated and
discharged with oral treatment. Two weeks later the
patient was readmitted due to spiking fever, arthralgias
and maculopapular rashes on her palms. A physical exam-
ination revealed jaundiced eyes and her laboratory tests
showed serious liver dysfunction, with ALT 791 U/l, AST
611 U/l, alkaline phosphatase 404 U/l, GGTP 2105 U/l,
LDH 1683 U/l, and total serum bilirubin at 177 micro-
mol/l. An abdominal ultrasonography revealed that the
patient had a normal size liver with a 16.5 cm enlarged
spleen and normal pancreas and common bile duct. Her
kidneys also appeared normal. Repeat blood tests showed
leukopenia of 3200, which further declined to 1100,Journal of Medical Case Reports 2009, 3:138 http://www.jmedicalcasereports.com/content/3/1/138
Page 3 of 5
(page number not for citation purposes)
hemoglobin 11 gr%, platelets 217,000, ESR 92, CRP 4 and
ferritin 2680 ng/ml. Her lipid profile disclosed hypercho-
lesterolemia of 15.1 mmol/l (normal range 3 to 5 mmol/
l), HDL 1.66 mmol/l (normal value > 0.91 mmol/l), LDL
11.11 mmol/l (normal range 0 to 3.4 mmol/l) and hyper-
triglyceridemia 5.0 mmol/l (normal range 0 to 2.3 mmol/
l).
PCR tests for CMV, EBV and HSV were also repeated and
gave negative results. The biomarkers test was also
repeated and showed her serum level of beta 2 microglob-
ulin to be higher than 9000 mg/ml (normal value <2000).
Her serum IL-2R was 850 IU/ml (normal value <500 IU/
ml) and serum TNF was lower than 20 pg/ml. A liver
biopsy was then performed and showed a mild chronic
inflammatory infiltration with no evidence of bile tract
enlargement, foamy macrophage (hypercholesterolemia
hypertriglyceridemia state), mild sinusoidal fibrosis and
macrophage with intracellular iron pigmentation.
The official interpretation of the patient's condition was
that of non-specific changes. An additional BM biopsy
with aspiration was performed, again indicating severe
hemophagocytosis. The patient was treated again with
cyclosporine 5 mg/kg, solumedrol 1 g for three days and
mycophenolate mofetil 500 mg three times daily. With
this treatment the clinical conditions and the laboratory
tests of the patient improved and she was discharged with
the treatment of oral prednisone, cyclosporine and myco-
phenolate mofetil.
For the last 20 months the patient has remained com-
pletely asymptomatic while being treated with prednisone
5 mg per day (after a very slow tempering) and
cyclosporine 75 mg per 2 days. Eight months after she
recommenced this treatment, the prescription for myco-
phenolate mofetil was stopped.
Discussion
Still's disease (SD) was described for the first time in chil-
dren by George Still in 1896. It is characterized by a fever
of approximately 39°C which continues for more than
seven days, arthralgias or arthritis of two weeks duration
or longer, and macular and/or maculopapular rash which
is non-pruritic and salmon pink in color. Sore throat,
lymph node swelling, hepatomegaly and/or splenomeg-
aly with abnormal liver function studies, may also be
present [3]. Typically, laboratory studies show an elevated
ESR, which is accompanied by leukocytosis with the pre-
dominance of granulocytes. Normocytic normochromic
anemia with hemoglobin values less than 10 g/dl and
reactive thrombocytosis are seen in the majority of
patients. Altered liver function studies are relatively com-
mon. However, liver biopsy findings are usually non-spe-
cific [4].
The serum ferritin level is high in patients with SD, with
values of 2,500 to 10,000 or even higher in 70% of
patients reported. These high levels most probably reflect
an acute phase response, since hepatocytes responding to
inflammatory cytokines increase ferritin synthesis [5].
Since ferritin levels are not that high in other rheumato-
logic diseases, it was suggested as a candidate for a sero-
logic marker for the diagnosis and monitoring of the
response to treatment of SD. However, other studies sug-
gest that the portion of glycosylated ferritin (less than
20% of the total value of ferritin) is a more specific finding
for the diagnosis of SD, in contrast to other rheumatologic
diseases where the value is much higher [6]. Interleukin-
6, TNF alpha, interferon gamma and interleukin 18 may
be elevated during the active phase of the disease, but
serology for antinuclear antibody and rheumatoid factor
are negative [7].
The etiology of the disease is unknown and a variety of
infectious triggers have been suggested including rubella,
echovirus 7, mumps, cytomegalovirus, Epstein-Barr virus,
adenovirus, parainfluenza, parvovirus, Coxsackie, influ-
enza, herpes, and hepatitis B and C [8]. Possible bacterial
etiology including Yersinia enterocolitica and mycoplasma
pneumonia has also been raised [9]. Genetic factors such
as HLA-B17, B18, B35 and DR-2 have been suggested as a
predisposition for SD [10].
The diagnosis of SD is made using major and minor crite-
ria. However, it requires the exclusion of infectious mono-
nucleosis or parvovirus B19 infection, malignancy
(particularly lymphoma), or other rheumatologic diseases
such as polyarthritis nodosa and systemic lupus ery-
thematosus [2].
Macrophage activating syndrome (MAS) is a severe,
potentially life-threatening condition which may compli-
cate chronic rheumatic diseases, especially systemic onset
juvenile chronic arthritis. MAS is characterized by fever,
hepatosplenomegaly, lymphadenopathy, severe cytope-
nia, serious liver dysfunction, coagulopathy and neuro-
logic involvement. Early diagnosis of this condition is
important because of the disease's aggressive clinical
course.
Clinical and biological features of MAS closely resemble
reactive hemophagocytic lymphohistocytosis (HLH) and
the disease is in fact considered today as a subclass of HLH
(secondary), which is induced by heterogeneous disorders
including infections, malignant tumors and medications
such as gold therapy, Aspirin and other non steroidal anti-
inflammatory drugs [11]. The exact underlying mecha-
nisms of MAS have not yet been clarified.Journal of Medical Case Reports 2009, 3:138 http://www.jmedicalcasereports.com/content/3/1/138
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The diagnosis of MAS in a patient known to have a rheu-
matic disease must be suspected when the patient shows
signs of systemic derangement, fever, hepatosplenomeg-
aly, bleeding tendency, leukopenia, thrombocytopenia,
increase in liver enzyme values and coagulations distur-
bance [12]. Hypofibrinogenemia is one of the most
important clues for the diagnosis of MAS since patients
usually have high fibrinogen levels due to their underly-
ing inflammatory disease. An increased fibrinolysis is
most probably due to uncontrolled activation of the mac-
rophages and the production of plasminogen. A decrease
in factor II and factor VII + X values is also observed in
some reported cases [13]. A bone marrow smear may
show macrophage hemophagocytosis. Another biological
indicator of MAS is an increased level of serum triglyceride
that can be related to the patient's extensive production of
cytokines, such as tumor necrosis factor alpha, which
reduce the lipoprotein lipase activity. Interleukin-1 and
interferon gamma are also overproduced in a patient with
MAS [1].
In 1994, the Histocyte Society conducted the first interna-
tional treatment study for patients with HLH and they rec-
ommended treatment with etoposide 150 mg/2 M twice a
week for two weeks, dexamethasone 10 mg/2 M also for
two weeks, cyclosporine 3 mg/kg to 5 mg/kg for a long
period and metotrexate in cases where the patient's nerv-
ous system is already affected. In resistant cases, several
modes of therapy were described including high dose ster-
oids, cyclosporine, antihuman thymocyte globulin
(ATG), intravenous immune globulin (IVIG), plasma
exchange and allogeneic bone marrow transplantation
[14]. Recently, IL-1 beta receptor antagonist (Anakinra)
was used with success in severe cases of HLH [15].
Conclusion
This case is remarkable for its special pattern of an acute
relapsing MAS. The exact mechanism underlying the
relapsing pattern of the disease is not well understood.
However, our patient fully recovered following long-term
treatment with steroids, mycophenolate mofetil and
cyclosporine. We cannot evaluate the exact contribution
of each medication to the patient's positive response. Nev-
ertheless, we believe that the prolonged use of
cyclosporine treatment played a major role in her recov-
ery.
We recommend continuing treatment with cyclosporine
for several weeks following the patient's clinical and labo-
ratory recovery in order to prevent a MAS relapse. Treat-
ment with IL-1 beta receptor antagonists should also be
considered in future cases.
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